Posted On: 12/13/2013 12:44:41 PM
Post# of 89346
$NKTR News
AstraZeneca's NDA for Naloxegol accepted 3:35 a.m. Nov. 19, 2013 - MarketWatch.com
Nektar Therapeutics shares soar on earnings, new drug prospects 12:31 p.m. Nov. 8, 2013 - Russ Britt
Rough market day for Nektar, while Pharmacyclics and Regeneron soar 5:21 p.m. Sept. 26, 2013 - Russ Britt
Nike shares swoosh higher after earnings 4:53 p.m. Sept. 26, 2013 - Wallace Witkowski
Nektar shares drop 25% after study misses endpoint 3:45 p.m. Sept. 26, 2013 - Wallace Witkowski
FDA grants fast-track status for Nektar drug 10:43 a.m. Nov. 7, 2012 - MarketWatch.com
S&P 500 clears trendline resistance 10:01 a.m. July 30, 2012 - Michael Ashbaugh
Charting the latest tape bomb 10:02 a.m. July 23, 2012 - Michael Ashbaugh
Wednesday’s biggest gaining & declining stocks 5:04 p.m. Feb. 29, 2012 - Kate Gibson
Nektar sells royalties for two drugs 11:31 a.m. Feb. 29, 2012 - MarketWatch.com
S&P 500 vacillates at the March peak 9:47 a.m. April 4, 2011 - Michael Ashbaugh
Wednesday’s biggest gaining and declining stocks 4:24 p.m. Jan. 19, 2011 - Kate Gibson
Monday’s biggest gaining and declining stocks 4:24 p.m. Dec. 13, 2010 - Kate Gibson
Drug indexes hug the flat line 10:57 a.m. Dec. 13, 2010 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 4:40 p.m. March 3, 2010 - MarketWatch
Nasdaq hesitates at the 50-day moving average 9:46 a.m. Feb. 18, 2010 - Michael Ashbaugh
S&P 500 settling into the 2004 trading range? 11:38 a.m. Feb. 1, 2010 - Michael Ashbaugh
S&P pulls in from the 1,100 mark 9:15 a.m. Oct. 16, 2009 - Michael Ashbaugh
U.S. benchmarks survive initial test of the 50-day 9:19 a.m. Oct. 5, 2009 - Michael Ashbaugh
Miners, banks weigh on U.K. market 11:07 a.m. Sept. 21, 2009 - Simon Kennedy
Timing And Good Science: Is Now The Time To Get On Board With Nektar? 11:18 a.m. Dec. 3, 2013 - Seeking Alpha
UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected Attractive Returns 9:53 a.m. Nov. 27, 2013 - benzinga.com
Healthcare coverage initiations roundup 8:55 a.m. Nov. 27, 2013 - Seeking Alpha
FDA to Review Nektar/AZN Drug - Analyst Blog 6:35 p.m. Nov. 20, 2013 - Zacks.com
US Stock Futures Edge Lower Ahead Of Earnings 6:53 a.m. Nov. 19, 2013 - benzinga.com
Nektar, Astra Zeneca Announce NDA for Naloxegol Accepted by FDA 6:07 a.m. Nov. 19, 2013 - benzinga.com
Baxter Advances on Pivotal Study - Analyst Blog 3:10 p.m. Nov. 15, 2013 - Zacks.com
Narrower-than-Expected Q3 Loss at Nektar - Analyst Blog 4:30 p.m. Nov. 8, 2013 - Zacks.com
Nektar Therapeutics' CEO Discusses Q3 2013 Results - Earnings Call Transcript 9:54 p.m. Nov. 7, 2013 - Seeking Alpha
10-Q: NEKTAR THERAPEUTICS 5:10 p.m. Nov. 7, 2013 - Edgar Online - (EDG = 10Q, 10K)
Short Interest In Nektar Therapeutics Falls 12.5% 2:49 p.m. Oct. 11, 2013 - TheStreet.com
Should Investors Have A Sweet Tooth For Nektar? 1:34 p.m. Oct. 11, 2013 - Seeking Alpha
Pipeline Update at Nektar - Analyst Blog 3:45 p.m. Oct. 9, 2013 - Zacks.com
Oversold Conditions For Nektar Therapeutics (NKTR) 12:06 p.m. Oct. 9, 2013 - TheStreet.com
Nektar Therapeutics' CEO Hosts Investor and Analyst R&D Day Conference (Transcript) 6:35 p.m. Oct. 8, 2013 - Seeking Alpha
Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day 10:15 a.m. Oct. 8, 2013 - benzinga.com
Pipeline Progresses at AstraZeneca - Analyst Blog 5:00 p.m. Sept. 30, 2013 - Zacks.com
Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's "Dead Cat Bounce" Stock 10:38 a.m. Sept. 30, 2013 - TheStreet.com
Nektar Reports AstraZeneca Receives EMA Acceptance of Marketing Authorization Application for Naloxegol 4:41 a.m. Sept. 30, 2013 - benzinga.com
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:07 p.m. Sept. 27, 2013 - TheStreet.com
New Research Arrangements, Investor Conference Schedules, Reimbursement Agreements, and NDA Acceptances - Research Report on Quintiles, Insys, HeartWare, Given Imaging, and Nektar 8:00 a.m. Nov. 28, 2013 - PR Newswire
Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar 8:00 a.m. Nov. 20, 2013 - PR Newswire
Morning Research: Inovio Pharma Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 9:03 a.m. Nov. 19, 2013 - PR Newswire
New Drug Application For Naloxegol Accepted By United States Food And Drug Administration 7:00 a.m. Nov. 19, 2013 - PR Newswire
Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 9:34 a.m. Nov. 13, 2013 - PR Newswire
Baxter Completes Enrollment in Phase III Clinical Trial of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A 9:00 a.m. Nov. 13, 2013 - BusinessWire
Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn 8:00 a.m. Nov. 12, 2013 - PR Newswire
Critical Alerts For Salix Pharmaceuticals, Endo Pharmaceuticals, Nektar Therapeutics, Riverbed Technology, and Ubiquiti Networks Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013 4:15 p.m. Nov. 7, 2013 - PR Newswire
Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets 5:00 p.m. Oct. 30, 2013 - PR Newswire
Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 9:00 a.m. Oct. 28, 2013 - PR Newswire
Nektar and Roswell Park Cancer Institute Announce Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Second-Line Treatment in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC) 8:00 a.m. Oct. 24, 2013 - PR Newswire
Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte, and Nektar 8:00 a.m. Oct. 16, 2013 - PR Newswire
AstraZeneca Announces New Safety Data For Naloxegol In Patients with Opioid-Induced Constipation 10:26 a.m. Oct. 14, 2013 - BusinessWire
Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day 11:15 a.m. Oct. 8, 2013 - PR Newswire
Regulatory Approvals, Public Offerings and Clinical Trial Results - Research Report on Theravance, Synageva, Nektar, Clovis Oncology, and ImmunoGen 8:00 a.m. Oct. 7, 2013 - PR Newswire
Nektar to Host Investor and Analyst R&D Day in New York City 8:30 p.m. Oct. 2, 2013 - PR Newswire
Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus 8:00 a.m. Oct. 2, 2013 - PR Newswire
Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol 5:30 a.m. Sept. 30, 2013 - PR Newswire
Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee 4:10 p.m. Sept. 26, 2013 - PR Newswire
AstraZeneca's NDA for Naloxegol accepted 3:35 a.m. Nov. 19, 2013 - MarketWatch.com
Nektar Therapeutics shares soar on earnings, new drug prospects 12:31 p.m. Nov. 8, 2013 - Russ Britt
Rough market day for Nektar, while Pharmacyclics and Regeneron soar 5:21 p.m. Sept. 26, 2013 - Russ Britt
Nike shares swoosh higher after earnings 4:53 p.m. Sept. 26, 2013 - Wallace Witkowski
Nektar shares drop 25% after study misses endpoint 3:45 p.m. Sept. 26, 2013 - Wallace Witkowski
FDA grants fast-track status for Nektar drug 10:43 a.m. Nov. 7, 2012 - MarketWatch.com
S&P 500 clears trendline resistance 10:01 a.m. July 30, 2012 - Michael Ashbaugh
Charting the latest tape bomb 10:02 a.m. July 23, 2012 - Michael Ashbaugh
Wednesday’s biggest gaining & declining stocks 5:04 p.m. Feb. 29, 2012 - Kate Gibson
Nektar sells royalties for two drugs 11:31 a.m. Feb. 29, 2012 - MarketWatch.com
S&P 500 vacillates at the March peak 9:47 a.m. April 4, 2011 - Michael Ashbaugh
Wednesday’s biggest gaining and declining stocks 4:24 p.m. Jan. 19, 2011 - Kate Gibson
Monday’s biggest gaining and declining stocks 4:24 p.m. Dec. 13, 2010 - Kate Gibson
Drug indexes hug the flat line 10:57 a.m. Dec. 13, 2010 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 4:40 p.m. March 3, 2010 - MarketWatch
Nasdaq hesitates at the 50-day moving average 9:46 a.m. Feb. 18, 2010 - Michael Ashbaugh
S&P 500 settling into the 2004 trading range? 11:38 a.m. Feb. 1, 2010 - Michael Ashbaugh
S&P pulls in from the 1,100 mark 9:15 a.m. Oct. 16, 2009 - Michael Ashbaugh
U.S. benchmarks survive initial test of the 50-day 9:19 a.m. Oct. 5, 2009 - Michael Ashbaugh
Miners, banks weigh on U.K. market 11:07 a.m. Sept. 21, 2009 - Simon Kennedy
Timing And Good Science: Is Now The Time To Get On Board With Nektar? 11:18 a.m. Dec. 3, 2013 - Seeking Alpha
UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected Attractive Returns 9:53 a.m. Nov. 27, 2013 - benzinga.com
Healthcare coverage initiations roundup 8:55 a.m. Nov. 27, 2013 - Seeking Alpha
FDA to Review Nektar/AZN Drug - Analyst Blog 6:35 p.m. Nov. 20, 2013 - Zacks.com
US Stock Futures Edge Lower Ahead Of Earnings 6:53 a.m. Nov. 19, 2013 - benzinga.com
Nektar, Astra Zeneca Announce NDA for Naloxegol Accepted by FDA 6:07 a.m. Nov. 19, 2013 - benzinga.com
Baxter Advances on Pivotal Study - Analyst Blog 3:10 p.m. Nov. 15, 2013 - Zacks.com
Narrower-than-Expected Q3 Loss at Nektar - Analyst Blog 4:30 p.m. Nov. 8, 2013 - Zacks.com
Nektar Therapeutics' CEO Discusses Q3 2013 Results - Earnings Call Transcript 9:54 p.m. Nov. 7, 2013 - Seeking Alpha
10-Q: NEKTAR THERAPEUTICS 5:10 p.m. Nov. 7, 2013 - Edgar Online - (EDG = 10Q, 10K)
Short Interest In Nektar Therapeutics Falls 12.5% 2:49 p.m. Oct. 11, 2013 - TheStreet.com
Should Investors Have A Sweet Tooth For Nektar? 1:34 p.m. Oct. 11, 2013 - Seeking Alpha
Pipeline Update at Nektar - Analyst Blog 3:45 p.m. Oct. 9, 2013 - Zacks.com
Oversold Conditions For Nektar Therapeutics (NKTR) 12:06 p.m. Oct. 9, 2013 - TheStreet.com
Nektar Therapeutics' CEO Hosts Investor and Analyst R&D Day Conference (Transcript) 6:35 p.m. Oct. 8, 2013 - Seeking Alpha
Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day 10:15 a.m. Oct. 8, 2013 - benzinga.com
Pipeline Progresses at AstraZeneca - Analyst Blog 5:00 p.m. Sept. 30, 2013 - Zacks.com
Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's "Dead Cat Bounce" Stock 10:38 a.m. Sept. 30, 2013 - TheStreet.com
Nektar Reports AstraZeneca Receives EMA Acceptance of Marketing Authorization Application for Naloxegol 4:41 a.m. Sept. 30, 2013 - benzinga.com
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:07 p.m. Sept. 27, 2013 - TheStreet.com
New Research Arrangements, Investor Conference Schedules, Reimbursement Agreements, and NDA Acceptances - Research Report on Quintiles, Insys, HeartWare, Given Imaging, and Nektar 8:00 a.m. Nov. 28, 2013 - PR Newswire
Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar 8:00 a.m. Nov. 20, 2013 - PR Newswire
Morning Research: Inovio Pharma Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 9:03 a.m. Nov. 19, 2013 - PR Newswire
New Drug Application For Naloxegol Accepted By United States Food And Drug Administration 7:00 a.m. Nov. 19, 2013 - PR Newswire
Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 9:34 a.m. Nov. 13, 2013 - PR Newswire
Baxter Completes Enrollment in Phase III Clinical Trial of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A 9:00 a.m. Nov. 13, 2013 - BusinessWire
Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn 8:00 a.m. Nov. 12, 2013 - PR Newswire
Critical Alerts For Salix Pharmaceuticals, Endo Pharmaceuticals, Nektar Therapeutics, Riverbed Technology, and Ubiquiti Networks Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013 4:15 p.m. Nov. 7, 2013 - PR Newswire
Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets 5:00 p.m. Oct. 30, 2013 - PR Newswire
Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 9:00 a.m. Oct. 28, 2013 - PR Newswire
Nektar and Roswell Park Cancer Institute Announce Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Second-Line Treatment in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC) 8:00 a.m. Oct. 24, 2013 - PR Newswire
Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte, and Nektar 8:00 a.m. Oct. 16, 2013 - PR Newswire
AstraZeneca Announces New Safety Data For Naloxegol In Patients with Opioid-Induced Constipation 10:26 a.m. Oct. 14, 2013 - BusinessWire
Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day 11:15 a.m. Oct. 8, 2013 - PR Newswire
Regulatory Approvals, Public Offerings and Clinical Trial Results - Research Report on Theravance, Synageva, Nektar, Clovis Oncology, and ImmunoGen 8:00 a.m. Oct. 7, 2013 - PR Newswire
Nektar to Host Investor and Analyst R&D Day in New York City 8:30 p.m. Oct. 2, 2013 - PR Newswire
Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus 8:00 a.m. Oct. 2, 2013 - PR Newswire
Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol 5:30 a.m. Sept. 30, 2013 - PR Newswire
Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee 4:10 p.m. Sept. 26, 2013 - PR Newswire
(0)
(0)
